Phase 2 OCD Trial, Recruiting NCT04131829 Sponsor: Yale University Condition: OCD
Back to Ocd

Phase 2 OCD Trial, Recruiting

NCT04131829
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult (any gender), and the study aims to recruit equal numbers of men and women, including people from different racial and ethnic backgrounds
  • You are able and willing to take part in all study activities, including health assessments and MRI brain scans
  • You have signed a consent form approved by the study's ethics committee
  • (For people with OCD) You have a confirmed diagnosis of OCD based on a clinical assessment
  • (For people with OCD) Your OCD symptoms are at least moderately severe, based on a standard symptom rating scale
  • (For people with OCD) You are not currently taking any psychiatric medications, except occasionally taking something to help with sleep
  • (For people with OCD) You are looking for treatment and your doctor considers a specific antidepressant medication (fluoxetine) appropriate for you
  • (For people with OCD who can become pregnant) You are not pregnant, not planning to become pregnant, and are willing to use reliable contraception throughout the study
  • (For healthy volunteers) You do not have any current mental health diagnosis and have no known or suspected family history of OCD, Tourette syndrome, hoarding disorder, body dysmorphic disorder, or compulsive grooming disorders in a close relative

Who may not be able to join:

  • You have an unstable medical, psychiatric, or neurological condition that may need urgent treatment, including serious concerns about suicide
  • You have had a substance use disorder (such as alcohol or drug dependency) in the past 6 months
  • You have taken psychiatric medications in the past 8 weeks (except occasionally using a sleep aid or painkiller)
  • You have taken a sleep aid or prescription painkiller within the past 3 days before a scan appointment
  • You have a history of a psychotic disorder or bipolar mania
  • A urine drug test shows evidence of substance use
  • You have a significant neurological disease or a history of serious head injury, including a concussion where you lost consciousness for an extended period
  • You are pregnant
  • You have any metal implants in your body or any other reason you cannot safely have an MRI scan
  • You have severe claustrophobia, significant back pain, or any condition that would make lying still in an MRI scanner for an extended period difficult
  • (For people with OCD) You have previously had an allergic reaction or bad reaction to fluoxetine or a similar antidepressant, or have another medical reason you should not take fluoxetine
  • (For people with OCD) You have already tried fluoxetine at a sufficient dose and length of time in the past and it did not work for you
  • (For people with OCD) You are currently taking blood-thinning medication (Coumadin/warfarin) or a type of antidepressant called MAOIs

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christopher Pittenger, MD, PhD, Professor of Psychiatry; Director, Yale OCD Research Clinic

Phone: 1-855-623-9253

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
14 October 2019
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Obsessive-compulsive severity change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov